UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 筋層非浸潤性膀胱癌の再発癌あるいは残存癌のマネージメント management of recurrent or persistent non muscle invasive bladder cancer
- 2. BCG膀胱内注入療法の感染性合併症 infectious complications of intravesical bcg immunotherapy
- 3. 原発性筋層非浸潤性膀胱癌の治療 treatment of primary non muscle invasive urothelial bladder cancer
- 4. 尿路上皮膀胱癌に対する根治的膀胱全摘除術および膀胱温存治療 radical cystectomy and bladder sparing treatments for urothelial bladder cancer
- 5. ウシ型結核菌 mycobacterium bovis
English Journal
- Standardization of BCG multiple puncture 40 mg and BCG live (intravesical) Theracys/BCG therapeutic Immucyst.
- Csizer Z, Herbert A, Guest N, Sparkes J, Barreto L, Harjee N, Langlois S.
- Developments in biological standardization. 1992 ;77()223-7.
- PMID 1426666
- Stability of BCG vaccine (intravesical) Theracys/BCG therapeutic ImmuCyst and its importance in clinical efficacy.
- Sparkes J, Guest N, Csizer Z, Barreto L.
- Developments in biological standardization. 1992 ;77()217-22.
- The manufacture of Therapeutic BCG can and should be a controlled process, to ensure adequate treatment doses are received by CIS patients. Standardization of production methods and CFU potency testing methods are essential to ensure continued successful treatment of CIS. Stability data can be used
- PMID 1426665
Related Links
- If TheraCys is administered within two weeks of either biopsy, TUR or traumatic bladder catheterization (associated with hematuria), a systemic BCG reaction is much more likely to occur. (5.1) If a bacterial urinary tract infection ...
- Learn about the prescription medication Theracys (BCG Live (Intravesical)), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. ... WARNING TheraCys®, BCG Live (Intravesical) contains live ...
Related Pictures
